Co-Diagnostics Q3 revenue $2.5M, net loss $6.0M; receives $9.0M Gates Foundation grant

Co-Diagnostics, Inc.

2023-Q3 EPS reported -$0.70 revenue$3,256,861

Revenue $2.5M, down from $5.1M in prior year due to declining COVID-19 test demand.
Net loss of $6.0M ($0.20/sh) vs $1.4M loss ($0.04/sh) in prior year.
Received $9.0M grant from Bill & Melinda Gates Foundation for TB test development on Co-Dx PCR platform.
Expects EUA submission to FDA for Co-Dx PCR Pro platform and COVID-19 assay by year-end 2023.
Cash and securities $63.4M as of Sept 30, 2023; repurchased 149,041 shares at $1.12 avg.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Co-Diagnostics, Inc. reported quarter ended September 30, 2023 results: revenue $2.5 million, net income $6.0 million, EPS $0.20 per fully diluted share.

Period: quarter ended September 30, 2023
Revenue: $2.5 million
Net income: $6.0 million
EPS: $0.20 per fully diluted share
Result: reported results

Exact text from the filing

the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 Financial Results: ● Revenue of $2.5 million, down from $5.1 million during the prior year primarily due to the anticipated decline in global demand for COVID-19 tests. Grant revenue totaled $2.3 million while product

View on SEC.gov

Browse all earnings releases →

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.